Alfred Health

Running trials

• Recruiting

  Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

  NCT06163820· Phase 1/2· Source

• Not yet recruiting

  A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.

  NCT07266324· Phase 2· Source

• Recruiting

  An Open-label Study to Evaluate Safety, Tolerability, and Efficacy of CB03-154 in Subjects Diagnosed With Epilepsy

  NCT07238868· Phase 2· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Source

• Recruiting

  Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  NCT06850727· Phase 2· Source

• Recruiting

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· Phase 3· Source

• Recruiting

  Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis

  NCT06934252· Phase 1· Source

• Recruiting

  An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)

  NCT06951217· Phase 2· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

  NCT06732180· Phase 1· Source

• Active, not recruiting

  Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01

  NCT06727565· Phase 2· Source

• Active, not recruiting

  Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

  NCT06501625· Phase 1/2· Source

• Recruiting

  BMB-101 in Absence Epilepsy and DEE

  NCT06401538· Phase 2· Source

• Active, not recruiting

  A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis

  NCT06550076· Phase 3· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, and Efficacy of CB03-154 in Adult Patients With Focal Epilepsy

  NCT06612775· Phase 2· Source

• Active, not recruiting

  A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

  NCT06329401· Phase 2· Source

• Enrolling by invitation

  5-SENSE Score Validation Study

  NCT06138808· Source

• Active, not recruiting

  RESEARCH EVALUATING VAGAL EXCITATION AND ANATOMICAL LINKS

  NCT06143293· Source

• Active, not recruiting

  IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma

  NCT05987332· Phase 2/3· Source

• Active, not recruiting

  A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

  NCT05257083· Phase 3· Source

• Recruiting

  IKS014 in Advanced Solid Tumors That Express HER2

  NCT05872295· Phase 1· Source

• Recruiting

  A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

  NCT06051409· Phase 3· Source

• Active, not recruiting

  A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

  NCT06052267· Phase 3· Source

• Active, not recruiting

  (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

  NCT05907954· Phase 2· Source

• Recruiting

  A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

  NCT05789082· Phase 1/2· Source

• Recruiting

  Markerless Image Guidance Using Intrafraction Kilovoltage X-ray Imaging

  NCT04086082· Source

• Active, not recruiting

  EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)

  NCT06923761· Phase 1/2· Source

• Recruiting

  A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies

  NCT05643742· Phase 1/2· Source

• Recruiting

  LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

  NCT05184790· Source

• Recruiting

  Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

  NCT05549297· Phase 3· Source

• Active, not recruiting

  Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial

  NCT05556720· Phase 3· Source

• Enrolling by invitation

  Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

  NCT04905693· Phase 3· Source

• Recruiting

  Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults

  NCT05219617· Phase 3· Source

• Recruiting

  Extending the Time Window for Tenecteplase by Recanalization of Basilar Artery Occlusion in Posterior Circulation Stroke

  NCT05105633· Phase 2/3· Source

• Active, not recruiting

  A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

  NCT05050097· Phase 1· Source

• Active, not recruiting

  A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

  NCT04923893· Phase 3· Source

• Active, not recruiting

  Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma

  NCT04949113· Phase 3· Source

• Active, not recruiting

  STrategies for Catheter Ablation of peRsistent Atrial Fibrlllation

  NCT04428944· Source

• Active, not recruiting

  A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

  NCT04722146· Phase 1· Source

• Active, not recruiting

  Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients

  NCT04385732· Source

• Active, not recruiting

  A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

  NCT04607421· Phase 3· Source

• Active, not recruiting

  Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

  NCT04623541· Phase 1/2· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation

  NCT04449874· Phase 1· Source

• Active, not recruiting

  A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

  NCT04181827· Phase 3· Source

• Active, not recruiting

  A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

  NCT02993523· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Epilepsy5 recruiting
• Idiopathic pulmonary fibrosis2 recruiting
• Lung cancer2 recruiting
• Melanoma2 recruiting
• Alzheimer disease1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Chronic lymphocytic leukaemia1 recruiting
• Follicular lymphoma1 recruiting
• Gastric and esophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Kidney cancer1 recruiting
• Liver and biliary tract cancer1 recruiting
• Mantle cell lymphoma1 recruiting
• Myelodysplastic syndromes1 recruiting
• Pancreatic cancer1 recruiting
• Parkinson disease1 recruiting
• Prostate cancer1 recruiting
• Stroke1 recruiting
• Ulcerative colitis1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Terminated

  A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma

  NCT07076550· Phase 1· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Source

• Completed

  A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

  NCT05665530· Phase 1· Source

• Recruiting

  Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

  NCT05727176· Phase 2· Source

• Terminated

  A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease

  NCT05744401· Phase 2· Source

• Completed

  Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy

  NCT05626634· Phase 2· Source

• Completed

  Multinational Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis

  NCT05255991· Phase 3· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Source

• Completed

  Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies

  NCT05364021· Phase 1/2· Source

• Terminated

  Study of Magrolimab Combination Therapy in Patients With Head and Neck Squamous Cell Carcinoma

  NCT04854499· Phase 2· Source

• Recruiting

  Bone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults

  NCT04608630· Phase 2· Source

• Completed

  Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

  NCT03867084· Phase 3· Source

• Completed

  Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005)

  NCT03797326· Phase 2· Source

• Completed

  A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin Lymphoma

  NCT03331731· Phase 2· Source

• Completed

  Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

  NCT03739931· Phase 1· Source

• Completed

  A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

  NCT03507790· Phase 2· Source

• Completed

  A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03277105· Phase 3· Source

• Completed

  Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001)

  NCT03179436· Phase 1/2· Source

Trial sites

• Alfred Health55 trials
• Alfred Health /ID# 1542751 trial
• Alfred Health, Medical Oncology Unit, Second floor William Buckland Radiotherapy Center1 trial
• Alfred Health (Site 0018)1 trial
• Alfred Health (Site 0230)1 trial
• Alfred Health (Site 0902)1 trial
• Victorian Melanoma Service, Alfred Health1 trial
• Alfred Health2 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Epilepsy53 works · 9 trials
• Chronic lymphocytic leukaemia7 works · 4 trials